Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 13/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 12/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18186339 | 1.00 | NR1H2 (0.47) | NR1H2NR1H3HDAC1GPR119MAP4K4 | |
| SCHEMBL16824946 | 1.00 | NR1H2 (0.47) | NR1H2NR1H3HDAC1GPR119MAP4K4 | |
| SCHEMBL16824975 | 0.88 | NR1H2 (0.48) | NR1H2NR1H3HDAC1GPR119MAP4K4 | |
| SCHEMBL16569865 | 0.88 | NR1H2 (0.48) | NR1H2NR1H3HDAC1GPR119MAP4K4 | |
| SCHEMBL18186418 | 0.88 | NR1H2 (0.48) | NR1H2NR1H3HDAC1GPR119MAP4K4 | |
| SCHEMBL18186416 | 0.88 | NR1H2 (0.48) | NR1H2NR1H3HDAC1GPR119MAP4K4 | |
| SCHEMBL18186381 | 0.85 | MAPT (0.60) | NR1H2NR1H3ALDH1A1LMNAMAPT | |
| SCHEMBL18186373 | 0.85 | MAPT (0.60) | NR1H2NR1H3ALDH1A1LMNAMAPT | |
| SCHEMBL18186372 | 0.85 | MAPT (0.60) | NR1H2NR1H3ALDH1A1LMNAMAPT | |
| SCHEMBL27979284 | 0.84 | NR1H2 (0.46) | NR1H2NR1H3HDAC1GPR119MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850247-B2 | Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors | ALMAC HOUSE (GB) | 2017-12-26 | — | — | US | disclosed |
| EP-3083625-B1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LTD (GB) | 2017-11-01 | — | — | EP | disclosed |
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | WEE1, WEE2, NME1 | NR1H2 4618/4885NR1H3 4524/4885HDAC1 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.